PharmaCord, a provider of patient services for the biopharmaceutical industry, and Mercalis, an integrated life sciences commercialization partner, announced a merger to create one of the largest independent total solutions providers to the biopharmaceutical industry. The combined company will be a provider that offers a full suite of solutions, from patient services to market access, supporting the entire commercialization process.
PharmaCord is a pharma services company that serves as a commercialization partner for more than 30 biopharmaceutical organizations. Its solutions support the patient journey for specialty medications through a range of services that raise awareness, facilitate access to treatment, improve affordability, and promote therapy adherence. PharmaCord employs more than 1,100 team members and supports more than 100 biopharmaceutical products through its various programs.
Mercalis, a portfolio company of Odyssey Investment Partners, employs more than 1,800 associates who support more than 500 clients. Its integrated suite of services combines market access insights, technology-enabled patient support services, and healthcare provider engagement solutions to help customers bring new healthcare products to market.
By combining PharmaCord’s expertise in patient services with Mercalis’s advanced technology infrastructure, commercial team, and fully integrated market access offerings, the new entity is poised to be a leading provider of patient access solutions to the biopharmaceutical industry. The merger will enhance the patient experience by improving access and affordability while addressing the complex challenges of adherence and retention, particularly for specialty medications.
The combined company will be majority owned by funds advised by Permira. Robert Truckenmiller will serve as CEO of the combined company and Scott Dulitz will serve as president. The transaction, which is subject to customary regulatory approvals and closing conditions, is expected to close by the third quarter of 2025. Financial terms of the transaction were not disclosed.
